The Efficacy of Combined Povidone Iodine 1% and Dexamethasone 0.08% Prepared Eye Drops in Treating Post Viral Corneal Sub Epithelial Infiltrates Compared to Other Modalities of Treatments

Hassan Ali H
{"title":"The Efficacy of Combined Povidone Iodine 1% and Dexamethasone 0.08% Prepared Eye Drops in Treating Post Viral Corneal Sub Epithelial Infiltrates Compared to Other Modalities of Treatments","authors":"Hassan Ali H","doi":"10.46889/joar.2023.4203","DOIUrl":null,"url":null,"abstract":"Purpose: To Evaluate the efficacy of combination povidone-iodine 1.0% eye drops and dexamethasone 0.08% eye drops in the treatment of post viral corneal Sub Epithelial Infiltrates (SEIs).\n\nMaterials and methods: A prospective, randomized, controlled, comparative study was conducted at king Hussein medical center between 2020-2021. Patients who attended to the ophthalmology department suffering from SEIs were enrolled in the study; a written Informed consent was obtained from all enrolled patients. Inclusion criteria include; ≥ 18 years of age, SEIs duration more than one month and less than 6 months, one eye per patient were included in the study and naive eye. Exclusion criteria include; a history of thyroid disease, allergy to iodine or study medications, ocular surgery within the past 3 months, corneal dendrites, conjunctival membrane or pseudo membrane, active conjunctivitis, corneal ulceration, corneal abrasion, corneal foreign body, anterior chamber inflammation or pregnancy/lactating mother. Patients were randomly divided into three groups and treated for two weeks. In the first group, patients received combined povidone iodine 1% and dexamethasone 0.08% prepared eye drops with lubricant eye drops, the second group received dexamethasone 0.08% eye drops and lubricants eye drops and the third group received povidone iodine 1% eye drops and lubricant eye drops. The patients were followed up and evaluated at day zero, 2 weeks, 6 weeks, 6 months’ post treatment regarding; Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP), symptoms (visual blurring, photophobia, and foreign body sensation) and corneal sub epithelial infiltrates according to our scoring scale.\n\nResults: After conducting the inclusion and exclusion criteria, 45 eyes were included in the study (15 in each group). Povidone iodine 1% was well tolerated and safe in first and third groups. In first study group, a dramatic improvement in patients’ symptoms and SEIs scoring scale was observed (p < 0.05) in addition to a significant improvement in BCVA after 2 weeks of treatment. On the other side, no significant improvement has been achieved (p > 0.05) regarding BCVA, symptoms or SEIs scoring scale in the second and third groups.\n\nConclusion: Combined povidone iodine 1% and dexamethasone 0.08% prepared eye drops can improve signs and symptoms of SEIs in addition to a significant improvement in BCVA and speeding up the recovery compared to the other modalities of treatment used in this study.","PeriodicalId":348405,"journal":{"name":"Journal of Ophthalmology and Advance Research","volume":"27 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ophthalmology and Advance Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46889/joar.2023.4203","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To Evaluate the efficacy of combination povidone-iodine 1.0% eye drops and dexamethasone 0.08% eye drops in the treatment of post viral corneal Sub Epithelial Infiltrates (SEIs). Materials and methods: A prospective, randomized, controlled, comparative study was conducted at king Hussein medical center between 2020-2021. Patients who attended to the ophthalmology department suffering from SEIs were enrolled in the study; a written Informed consent was obtained from all enrolled patients. Inclusion criteria include; ≥ 18 years of age, SEIs duration more than one month and less than 6 months, one eye per patient were included in the study and naive eye. Exclusion criteria include; a history of thyroid disease, allergy to iodine or study medications, ocular surgery within the past 3 months, corneal dendrites, conjunctival membrane or pseudo membrane, active conjunctivitis, corneal ulceration, corneal abrasion, corneal foreign body, anterior chamber inflammation or pregnancy/lactating mother. Patients were randomly divided into three groups and treated for two weeks. In the first group, patients received combined povidone iodine 1% and dexamethasone 0.08% prepared eye drops with lubricant eye drops, the second group received dexamethasone 0.08% eye drops and lubricants eye drops and the third group received povidone iodine 1% eye drops and lubricant eye drops. The patients were followed up and evaluated at day zero, 2 weeks, 6 weeks, 6 months’ post treatment regarding; Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP), symptoms (visual blurring, photophobia, and foreign body sensation) and corneal sub epithelial infiltrates according to our scoring scale. Results: After conducting the inclusion and exclusion criteria, 45 eyes were included in the study (15 in each group). Povidone iodine 1% was well tolerated and safe in first and third groups. In first study group, a dramatic improvement in patients’ symptoms and SEIs scoring scale was observed (p < 0.05) in addition to a significant improvement in BCVA after 2 weeks of treatment. On the other side, no significant improvement has been achieved (p > 0.05) regarding BCVA, symptoms or SEIs scoring scale in the second and third groups. Conclusion: Combined povidone iodine 1% and dexamethasone 0.08% prepared eye drops can improve signs and symptoms of SEIs in addition to a significant improvement in BCVA and speeding up the recovery compared to the other modalities of treatment used in this study.
1%聚维酮碘联合0.08%地塞米松滴眼液治疗病毒性角膜上皮下浸润的疗效比较
目的:评价1.0%聚维酮碘滴眼液联合0.08%地塞米松滴眼液治疗病毒性角膜上皮下浸润(SEIs)的疗效。材料和方法:2020-2021年在侯赛因国王医疗中心进行了一项前瞻性、随机、对照、比较研究。在眼科就诊的SEIs患者被纳入研究;所有入组患者均获得书面知情同意书。入选标准包括;年龄≥18岁,SEIs持续时间大于1个月小于6个月,每例患者1只眼纳入研究和初发眼。排除标准包括:有甲状腺疾病史、碘或研究药物过敏史、近3个月内眼部手术史、角膜树突、结膜或假膜、活动性结膜炎、角膜溃疡、角膜磨损、角膜异物、前房炎症或妊娠/哺乳期母亲。患者随机分为三组,治疗两周。第一组患者给予1%聚维酮碘和0.08%地塞米松联合滴眼液加润滑剂滴眼液,第二组患者给予0.08%地塞米松滴眼液加润滑剂滴眼液,第三组患者给予1%聚维酮碘滴眼液加润滑剂滴眼液。分别于治疗后第0天、2周、6周、6个月对患者进行随访和评估;最佳矫正视力(BCVA)、眼压(IOP)、症状(视力模糊、畏光、异物感)和角膜上皮下浸润。结果:经纳入、排除标准处理,纳入45只眼(每组15只)。聚维酮碘1%在第一组和第三组耐受良好且安全。在第一个研究组,治疗2周后患者症状和SEIs评分显著改善(p < 0.05), BCVA显著改善。另一方面,第二组和第三组在BCVA、症状、SEIs评分量表方面均无显著改善(p > 0.05)。结论:与本研究使用的其他治疗方式相比,1%聚维酮碘联合0.08%地塞米松配制滴眼液可改善SEIs的体征和症状,并显著改善BCVA,加快恢复。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信